Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
JAK1 V658F cancer sensitive JAK1 Inhibitor - ATP competitive Ruxolitinib Preclinical Actionable In a preclinical study, transformed cells expressing JAK1 V658F were sensitive to ATP-competitive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331). 21393331
JAK1 V658F hematologic cancer sensitive SHP099 Preclinical Actionable In a preclinical study, SHP099 inhibited proliferation of a hematopoietic cancer cell line harboring JAK1 V658F in culture (PMID: 27362227). 27362227
JAK1 V658F hematologic cancer sensitive JAK1 Inhibitor - ATP competitive Ruxolitinib Preclinical - Cell culture Actionable In a preclinical study, Jakafi (ruxolitinib) inhibited Stat5 phosphorylation and viability in a cell line expressing JAK1 V658F in culture (PMID: 36786170). 36786170
JAK1 V658F hematologic cancer sensitive JAK1 Inhibitor - ATP competitive Ruxolitinib Preclinical - Cell culture Actionable In a preclinical study, Jakafi (ruxolitinib) inhibited proliferation of a cell line expressing JAK1 V658F in culture (PMID: 39091915). 39091915
JAK1 V658F hematologic cancer sensitive LGH447 Preclinical - Cell culture Actionable In a preclinical study, LGH447 inhibited viability and proliferation of transformed cells expressing JAK1 V658F in culture (PMID: 39033228). 39033228